drugset / Trial / NCT04557384

A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

NCT04557384

Phase 1 Terminated 3 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study in participants with advanced cancer is to learn more about the safety of ramucirumab when given by injection under the skin (subcutaneous injection). The study will also measure how much ramucirumab gets into the bloodstream and how long it takes the body to get rid of it.

Timeline

Start
2021-02-23
Primary completion
2021-05-25
Completion
2021-05-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramucirumab Monoclonal antibody 350 mg Subcutaneous

Indications